Genital epithelial barrier function is conserved by intravaginal rings releasing etonogestrel and ethinyl estradiol

References

• Boadu I. Coverage and determinants of modern contraceptive use in sub-Saharan Africa: further analysis of demographic and health surveys. Reprod Health. 2022; 19. 10.1186/s12978-022-01332-x.
   PubMed Web of Science ®Google Scholar
• UNAIDS. Women and HIV — a spotlight on adolescent girls and young women. 2019.
   Google Scholar
• Morrison CS, Chen P-L, Kwok C, Baeten JM, Brown J, Crook AM, Damme LV, Delany-Moretlwe S, Francis SC, Friedland BA, et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med. 2015; (1):4. doi:10.1371/journal.pmed.1001778.
   Web of Science ®Google Scholar
• Baeten JM, Benki S, Chohan V, Lavreys L, McClelland RS, Mandaliya K, Ndinya-Achola JO, Jaoko W, Overbaugh J. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS. 2007;21:1771–12. doi:10.1097/QAD.0b013e328270388a.
   PubMed Web of Science ®Google Scholar
• Polis CB, Curtis KM, Hannaford PC, Phillips SJ, Chipato T, Kiarie JN, Westreich DJ, Steyn PS. AIDS. 2016;30(17):2665–2683.
   PubMed Web of Science ®Google Scholar
• Ross JA, Agwanda AT. Increased use of injectable contraception in sub-Saharan Africa. Afr J Reprod Health. 2012;16:68–80.
   PubMedGoogle Scholar
• Vicetti Miguel RD, Quispe Calla NE, Cherpes TL HIV, progestins, genital epithelial barrier function, and the burden of objectivity†. Biol Reprod 2020; 103:318–322. 2 10.1093/biolre/ioaa078
   PubMed Web of Science ®Google Scholar
• Ahmed K, Baeten JM, Beksinska M, Bekker L-G, Bukusi EA, Donnell D, Gichangi PB, Heller KB, Hofmeyr GJ, Justman J, et al. 8.Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium (2019) HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet (London, England); 394:303–313. 10195 10.1016/S0140-6736(19)31288-7
   PubMed Web of Science ®Google Scholar
• Quispe Calla NE, Vicetti Miguel RD, Boyaka PN, Hall-Stoodley L, Kaur B, Trout W, Pavelko SD, Cherpes TL. Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection. Mucosal Immunol. 2016;9:1571–1583. doi:10.1038/mi.2016.22.
   PubMed Web of Science ®Google Scholar
• Quispe Calla NE, Vicetti Miguel RD, Aceves KM, Torres A, Cherpes TL Depot-medroxyprogesterone acetate reduces genital cell–cell adhesion molecule expression and increases genital herpes simplex virus type 2 infection susceptibility in a dose-dependent fashion. Contraception 2019; 100:397–401. 5 10.1016/j.contraception.2019.07.003
   PubMed Web of Science ®Google Scholar
• Bradley F, Boger MF, Kaldhusdal V, Ahlberg A, Edfeldt G, Lajoie J, Bergström S, Omollo K, Damdimopoulos A, Czarnewski P, et al. Multi-omics analysis of the cervical epithelial integrity of women using depot medroxyprogesterone acetate. PLoS Pathog 2022; 18:e1010494.10.1371/journal.ppat.1010494
   PubMed Web of Science ®Google Scholar
• Zalenskaya IA, Chandra N, Yousefieh N, Fang X, Adedipe OE, Jackson SS, Anderson SM, Mauck CK, Schwarts JL, Thurman AR, et al. Use of contraceptive depot medroxyprogesterone acetate is associated with impaired cervicovaginal mucosal integrity. J Clin Invest 2018; 128:4622–4638. 10 10.1172/JCI120583
   PubMed Web of Science ®Google Scholar
• Quispe Calla NE, Vicetti Miguel RD, Glick ME, Kwiek JJ, Gabriel JM, Cherpes TL. Exogenous oestrogen inhibits genital transmission of cell‐associated HIV‐1 in DMPA‐treated humanized mice. J Int AIDS Soc. 2018;21:e25063. doi:10.1002/jia2.25063.
   PubMed Web of Science ®Google Scholar
• Blue SW, Winchell AJ, Kaucher AV, Lieberman RA, Gilles CT, Pyra MN, Heffron R, Hou X, Coombs RW, Nanda K, et al. Simultaneous quantitation of multiple contraceptive hormones in human serum by LC–MS/MS. Contraception 2018; 97:363–369. 4 10.1016/j.contraception.2018.01.015
   PubMed Web of Science ®Google Scholar
• Timmer CJ, Mulders TMT. Pharmacokinetics of Etonogestrel and Ethinylestradiol released from a Combined Contraceptive Vaginal Ring. Clin Pharmacokinet. 2000;39:233–242. doi:10.2165/00003088-200039030-00005.
   PubMed Web of Science ®Google Scholar
• Quispe Calla NE, Vicetti Miguel RD, Fritts L, Miller CJ, Aceves KM, Cherpes TL. Exogenous sex steroids regulate genital epithelial barrier function in female rhesus macaques. Biol Reprod. 2020;103:310–317. doi:10.1093/biolre/ioaa105.
   PubMed Web of Science ®Google Scholar
• Quispe Calla NE, Vicetti Miguel RD, Trout W, Cherpes TL HIV and Hormonal contraception: bench and bedside. J Acquir Immune Defic Syndr 2017; 74:e85–86. 3 10.1097/QAI.0000000000001174
   PubMed Web of Science ®Google Scholar
• Hartig SM Basic Image Analysis and Manipulation in ImageJ. Current Protocols in Molecular Biology 2013. 102 1 10.1002/0471142727.mb1415s102
   Google Scholar
• Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab 1977; 44:32–38. 1 10.1210/jcem-44-1-32
   PubMed Web of Science ®Google Scholar
• Polis CB, Achilles SL, Hel Z, Hapgood JP Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women’s risk of HIV? Contraception 2018; 97:191–197. 3 10.1016/j.contraception.2017.12.003
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Depo-SubQ Provera 104 (medroxyprogesterone acetate) injectable suspension. New drug application no. 021583[J]. In: review. CfDEaRcpab (ed.); 2017.
   Google Scholar
• Global AIDS Response Progress Reporting (GARPR). Global AIDS update 2016. Switzerland: UNAIDS; 2017.
   Google Scholar
• Tsui AO, Brown W, Li Q. Contraceptive practice in sub-Saharan Africa. Popul Dev Rev. 2017;43:166–191. doi:10.1111/padr.12051.
   PubMed Web of Science ®Google Scholar
• Rehle T, Brinkmann UK, Siraprapasiri T, Coplan P, Aiemsukawat C, Ungchusak K Risk factors of HIV-1 infection among female prostitutes in Khon Kaen, Northeast Thailand. Infection 1992; 20:328–331. 6 10.1007/BF01710677
   PubMed Web of Science ®Google Scholar
• Vicetti Miguel R, Quispe Calla N, Aceves KM, Lopez F, Cherpes TL ECHO: context and limitations. Lancet (London, England) 2020; 395:e21. 10222 10.1016/S0140-6736(19)33107-1
   PubMedGoogle Scholar
• Radzio J, Hanley K, Mitchell J, Ellis S, Deyounks F, Jenkins LT, Hanson D, Heneine W, García-Lerma JG. Physiologic doses of depot-medroxyprogesterone acetate do not increase acute plasma simian HIV viremia or mucosal virus shedding in pigtail macaques. AIDS (London, England). 2014;28:1431–1439. doi:10.1097/QAD.0000000000000294.
   PubMed Web of Science ®Google Scholar
• Mishell DRJ. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med. 1996;41:381–390.
   PubMed Web of Science ®Google Scholar
• Bonny AE, Lange HL, Rogers LK, Gothard DM, Reed MD. A pilot study of depot medroxyprogesterone acetate pharmacokinetics and weight gain in adolescent females. Contraception. 2014;89:357–360. doi:10.1016/j.contraception.2014.01.017.
   PubMed Web of Science ®Google Scholar
• Mora G, Johansson ED. Plasma levels of medroxyprogesterone acetate (MPA), estradiol and progesterone in the rhesus monkey after intramuscular adminstration of Depo-Provera. Contraception. 1976;14(3):343–350. doi:10.1016/0010-7824(76)90101-3.
   PubMed Web of Science ®Google Scholar